Abstract
Fabry disease is an inborn error of glycolipid catabolism resulting from lesions in the gene encoding α-galactosidase (GLA). To elucidate the basis of Fabry disease, we constructed structural models of mutant GLAs responsible for the disease and calculated indexes, i.e., the numbers of atoms affected in the main chain and side chain of each mutant GLA, the root-mean-square distance values, and the solvent-accessible surface-area values, based on 212 Fabry amino acid substitutions previously reported (196 classic and 16 variant). As two therapeutic options, enzyme replacement and enzyme enhancement, are now available for this disease, proper prediction of the natural outcome and therapeutic efficiency based on the molecular evidence for individual cases are critical for patients’ quality of life. Our results revealed that structural changes in the classic Fabry group were generally large and tended to be in the core region of a protein or located in the functionally important region, including the active-site pocket. On the other hand, structural changes in the variant Fabry group were small or localized on the surface of the molecule far away from the active site. We focused on structural changes due to amino acid substitutions for which substrate analogues are effective for improving the stability or transportation of mutant GLAs, and the results of the study revealed that they are small or localized on the molecular surface, regardless of the phenotype. Coloring of affected atoms based on distances between wild type and mutant ones clearly showed the characteristic structural changes in the GLA protein geographically and subquantitatively. Structural investigation is useful for elucidation of the basis of Fabry disease and predicting disease outcome.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ashley GA, Shabbeer J, Yasuda M, Eng CM, Desnick RJ (2001) Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype. J Hum Genet 46:192–196
Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ (2000) Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 48:227–235
Bernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H, Desnick RJ (1989) Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest 83:1390–1399
Blanch LC, Meaney C, Morris CP (1996) A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene. Hum Mutat 8:38–43
Blaydon D, Hill J, Winchester B (2001) Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat 18:459
Calado J, Dickson J, Rueff J (2004) Human gene mutations. Hum Genet 115:347
Cooper A, Cooper JA, Wraith JE (2000) Human gene mutations. Hum Genet 107:535–536
Davies JP, Winchester BG, Malcolm S (1993) Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet 2:1051–1053
Davies J, Christomanou H, Winchester B, Malcolm S (1994) Detection of 8 new mutations in the alpha-galactosidase A gene in Fabry disease. Hum Mol Genet 3:667–669
Davies JP, Eng CM, Hill JA, Malcolm S, MacDermot K, Winchester B, Desnick RJ (1996) Fabry disease: fourteen alpha-galactosidase A mutations in unrelated families from the United Kingdom and other European countries. Eur J Hum Genet 4:219–224
Desnick RJ, Ioannou YA, Eng CM (2001) Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774
Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, Elleder M, Karetova D, Pavlikova M, Hrebicek M (2005) Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med 83:647–654
Dudek MJ, Ponder JW (1995) Accurate modeling of the intramolecular electrostatic energy of proteins. J Comput Chem 16:791–816
Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ (1993) Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53:1186–1197
Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ (1994) Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet 3:1795–1799
Eng CM, Ashley GA, Burgert TS, Enriquez AL, D’Souza M, Desnick RJ (1997) Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 3:174–182
Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Grodie S, Stacy CB, Mehta D, Parsons R, Norton K, O’Callaghan M, Desnick RJ (2001a) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711–722
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001b) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
Fan J-Q, Ishii S (2007) Active-site specific chaperone for Fabry disease; Yin and Yang of enzyme inhibitors. FEBS J 274:4962–4971
Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ (2001) Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy. N Engl J Med 345:25–32
Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337:319–335
Garman SC (2007) Structure-function relationships in alpha-galactosidase A. Acta Paediatr Suppl 96:6–16
Germain D, Biasotto M, Tosi M, Meo T, Kahn A, Poenaru L (1996) Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease. Hum Genet 98:719–726
Germain DP, Salard D, Fellmann F, Azibi K, Caillaud C, Bernard MC, Poenaru L (2001) Identification of a novel de novo mutation (G373D) in the alpha-galactosidase A gene (GLA) in a patient affected with Fabry disease. Hum Mutat 17:353
Germain DP, Shabbeer J, Cotigny S, Desnick RJ (2002) Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes. Mol Med 8:306–312
Guffon N, Froissart R, Chevalier-Porst F, Maire I (1998) Mutation analysis in 11 French patients with Fabry disease. Hum Mutat Suppl 1:S288–S290
Iga MI, Okayama A, Matsuyama M, Sasaki T, Murai K, Hashida S, Morishita K, Tsubouchi H (2001) Human gene mutations. Hum Genet 109:126
Ishii S, Sakuraba H, Suzuki Y (1992) Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet 89:29–32
Ishii S, Kase R, Sakuraba H, Suzuki Y (1993) Characterization of mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun 197:1585–1589
Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC, Fan JQ (2007) Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406:285–295
Kabsch W (1976) A solution for the best rotation to relate two sets of vectors. Acta Crystallogr A 32:827
Kabsch W (1978) A discussion of the solution for the best rotation to relate two sets of vectors. Acta Crystallogr A 34:922–923
Kase R, Bierfreund U, Klein A, Kolter T, Utsumi K, Itoh K, Sandhoff K, Sakuraba H (2000) Characterization of two alpha-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease. Biochem Biophys Res Commun 1501:227–235
Kimura K, Sato-Matsumura KC, Nakamura H, Onodera Y, Morita K, Enami N, Shougase T, Ohsaki T, Kato M, Takahashi T, Yamaguchi Y, Shimizu H (2002) A novel A97P amino acid substitution in alpha-galactosidase A leads to a classical Fabry disease with cardiac manifestations. Br J Dermatol 147:545–548
Koide T, Ishiura M, Iwai K, Inoue M, Kaneda Y, Okada Y, Uchida T (1990) A case of Fabry’s disease in a patient with no alpha-galactosidase A activity caused by a single amino acid substitution of Pro-40 by Ser. FEBS Lett 259:353–356
Kong MJ, Ponder JW (1997) Reaction field methods for off-center multipoles. J Chem Phys 107:481–492
Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Födinger M, Sunder-Plassmann G (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15:1323–1329
Kundrot CE, Ponder JW, Richards FM (1991) Algorithms for calculating excluded volume and its derivative as a function of molecular conformation and their use in energy minimization. J Comput Chem 12:402–409
Lai L, O’Meara M, Lien YH (2001) Human gene mutations. Hum Genet 109:469
Lee JK, Kim GH, Kim JS, Kim KK, Lee MC, Yoo HW (2000) Identification of four novel mutations in five unrelated Korean families with Fabry disease. Clin Genet 58:228–233
Matsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H (2005) Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotype. Hum Genet 117:317–328
McDonald IK, Thornton JM (1994) Satisfying hydrogen bonding potential in proteins. J Mol Biol 238:777–793
Miyazaki T, Kajita M, Ohmori S, Mizutani N, Niwa T, Murata Y, Seo H (1998) A novel mutation (E358K) in the alpha-galactosidase A gene detected in a Japanese family with Fabry disease. Hum Mutat Suppl 1:S139–S140
Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M, Feriozzi S, Gabrielli O, Barone R, Pistone G, Spisni C, Ricci R, Zammarchi E (2003) Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet 40:e103
Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H et al (1995) An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 333:288–93
Ohno K, Saito S, Sugawara K, Sakuraba H (2008) Structural consequences of amino acid substitutions causing Tay-Sachs disease. Mol Genet Metab (in press)
Okumiya T, Ishii S, Kase R, Kamei S, Sakuraba H, Suzuki Y (1995a) Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme protein. Hum Genet 95:557–561
Okumiya T, Ishii S, Takenaka T, Kase R, Kamei S, Sakuraba H, Suzuki Y (1995b) Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun 214:1219–1224
Okumiya T, Kawamura O, Itoh K, Kase R, Ishii S, Kamei S, Sakuraba H (1998) Novel missense mutation (M72 V) of alpha-galactosidase gene and its expression product in an atypical Fabry hemizygote. Hum Mutat Suppl 1:S213–S216
Pappu RV, Hart RW, Ponder JW (1998) Analysis and application of potential energy smoothing for global optimization. J Phy Chem B 102:9725–9742
Ploos van Amstel JK, Jansen RP, de Jong JG, Hamel BC, Wevers RA (1994) Six novel mutations in the alpha-galactosidase A gene in families with Fabry disease. Hum Mol Genet 3:503–505
Ren P, Ponder JW (2003) Polarizable atomic multipole water model for molecular mechanics simulation. J Phy Chem B 107:5933–5947
Rodríguez-Marí A, Coll MJ, Chabás A (2003) Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 2:258
Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM (2002) Prevalence of Anderson- Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407–1411
Saito S, Ohno K, Sugawara K, Sakuraba H (2008) Structural and clinical implications of amino acid substitutions in N-acetylgalactosamine-4-sulfatase: Insight into mucopolysaccharidosis type VI. Mol Genet Metab 93:419–425
Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, Nagao Y, Bishop DF, Desnick RJ, Suzuki Y (1990) Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 47:784–789
Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Lin H, Ohno K, Tanaka A, Yamada H, Uyama E (2000) Molecular and structural studies of the GM2 gangliosidosis O variant. J Hum Genet 47:176–183
Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Nakada H, Fukushige T, Kanzaki T (2004) Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J Hum Genet 49:1–8
Schäfer E, Baron K, Widmer U, Deegan P, Neumann HP, Sunder-Plassmann G, Johansson JO, Whybra C, Ries M, Pastores GM, Mehta A, Beck M, Gal A (2005) Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 25:412
Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365–370
Shabbeer J, Yasuda M, Luca E, Desnick RJ (2002) Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype. Mol Genet Metab 76:23–30
Shabbeer J, Robinson M, Desnick RJ (2005) Detection of alpha-galactosidase A mutations causing Fabry disease by denaturing high performance liquid chromatography. Hum Mutat 25:299–305
Shabbeer J, Yasuda M, Benson SD, Desnick RJ (2006) Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics 2:297–309
Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzon A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40
Sugawara K, Saito S, Ohno K, Okuyama T, Sakuraba H (2008) Structural study on mutant alpha-L-iduronidases: insight into mucopolysaccharidosis type I. J Hum Genet 53:467–474
Takata T, Okumiya T, Hayashibe H, Shimmoto M, Kase R, Itoh K, Utsumi K, Kamei S, Sakuraba H (1997) Screening and detection of gene mutations in Japanese patients with Fabry disease by non-radioactive single-stranded conformation polymorphism analysis. Brain Dev 19:111–116
Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ (1999) Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med 5:806–811
Verovnik F, Benko D, Vujkovac B, Linthorst GE (2004) Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Eur J Hum Genet 12:678–681
von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hübner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324:395–399
Weiner SJ, Kallman PA, Case DA, Singh UC, Ghio C, Alagona G, Profeta S, Weiner P (1984) A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc 106:765–784
Yam GH-F, Bosshard N, Zuber C, Steinmann B, Roth J (2006) Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am J Physiol Cell Physiol 290:C1076–C1082
Yang CC, Lai LW, Whitehair O, Hwu WL, Chiang SC, Lien YH (2003) Two novel mutations in the alpha-galactosidase A gene in Chinese patients with Fabry disease. Clin Genet 63:205–209
Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ (2003) Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 22:486–492
Acknowledgments
We thank Dr. J. Ponder (Department of Biochemistry and Molecular Biophysics, Washington University) for providing us with the TINKER software. We also thank I.K. McDonald, D. Naylor, D. Jones, J.M. Thornton, S. Hubbard, D.K. Smith, R. Laskowski, and G. Hutchinson for providing us with the HBPLUS. This work was partly supported by grants from the Japan Society for the Promotion of Science; the Ministry of Education, Science, Sports and Culture of Japan; the Ministry of Health and Welfare of Japan; the Japan Science and Technology Agency; and CREST.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclaimers: None.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Sugawara, K., Ohno, K., Saito, S. et al. Structural characterization of mutant α-galactosidases causing Fabry disease. J Hum Genet 53, 812–824 (2008). https://doi.org/10.1007/s10038-008-0316-9
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-008-0316-9
Keywords
This article is cited by
-
High-throughput screening identified disease-causing mutants and functional variants of α-galactosidase A gene in Japanese male hemodialysis patients
Journal of Human Genetics (2012)
-
Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase A structures in Fabry disease
Journal of Human Genetics (2011)
-
Biochemical and structural study on a S529V mutant acid α-glucosidase responsive to pharmacological chaperones
Journal of Human Genetics (2011)
-
Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information
Journal of Human Genetics (2010)
-
Structural modeling of mutant α-glucosidases resulting in a processing/transport defect in Pompe disease
Journal of Human Genetics (2009)
